Metsera Emerges as the Hottest Contender in the Obesity Drug Market
Metsera, a New York-based biotech company, has recently become the talk of the town in the obesity drug market. With Novo Nordisk and Pfizer engaged in a fierce bidding war to acquire access to Metsera’s pipeline of experimental treatments, the competition in the $150 billion weight-loss drug market is heating up.
One of the key attractions for both Novo Nordisk and Pfizer is Metsera’s lead candidate, MET-097i, a once-monthly GLP-1 injectable. Unlike existing treatments like Novo’s Wegovy and Eli Lilly’s Zepbound, which require weekly shots, MET-097i works by selectively binding to a protein pathway associated with weight loss and insulin release. This unique mechanism of action has the potential to reduce side effects and dosing frequency, making it a promising candidate in the obesity drug market.
Recent data from a mid-stage study showed that the highest dose of MET-097i helped patients lose an average of up to 14.1% of their body weight. Additionally, Metsera has another early-stage candidate, MET-233i, which targets the pancreatic hormone amylin, co-secreted with insulin. Analysts believe that these drugs could generate more than $5 billion in peak annual sales.
Founded in 2022 by Population Health Partners and ARCH Venture Partners, Metsera has garnered significant support from investors, including Google-parent Alphabet. With a market debut on Nasdaq in February at a $2.7 billion valuation, Metsera’s market capitalization has since doubled to $5.5 billion, with shares surging nearly 24% on Thursday.
The bidding war for Metsera, with Pfizer’s offer at $7.3 billion and Novo’s at up to $9 billion, signifies a new phase in the obesity drug race. This race was initially sparked in 2021 by Novo’s successful launch of Wegovy, the first highly effective obesity drug approved in the U.S. Since then, competition from Lilly and a wave of generic alternatives have impacted Wegovy’s sales, leading to a decline in Novo’s share price.
Investor interest in the obesity drug market remains strong, as evidenced by the positive impact of the Metsera bidding war on rival companies like Viking Therapeutics and Structure Therapeutics. Shares of these companies rose significantly, with Viking focusing on oral and injectable GLP-1 treatments and Structure developing an oral weight-loss pill. Altimmune, working on the pemvidutide injection, also saw a 4.5% increase in its share price.
In conclusion, the competition for Metsera highlights the growing importance of innovative treatments in the obesity drug market. As companies vie for a piece of this lucrative industry, the race to develop effective and safe weight-loss drugs is only expected to intensify in the coming years.
